Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Immunovaccine receives FDA fast track designation for DPX-Survivac

Dec. 11, 2014

Vaccinex's anti-SEMA4D antibody VX-15/2503 is well tolerated in patients with solid tumors

Dec. 10, 2014

Genmab confirms phase II study of daratumumab in non-Hodgkin's lymphomas

Dec. 9, 2014

Anti-CD19 MAb granted orphan status for diffuse large B-cell lymphoma

Dec. 5, 2014

FDA approves Blincyto to treat relapsed or refractory B-cell precursor ALL

Dec. 4, 2014

Phase I results reported for glioma vaccine SurVaxM

Dec. 4, 2014

Imugene updates preclinical findings for HER-Vaxx

Dec. 4, 2014

Unum Therapeutics initiates phase I trial of antibody-coupled T-cell receptor therapy

Dec. 3, 2014

GlaxoSmithKline presents preclinical data for the anti-HER3 antibody GSK-2849330

Dec. 2, 2014

Promising phase IIb results presented from the TIME trial evaluating TG-4010 in NSCLC

Dec. 2, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...